tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GB:0MGB Stock Latest News

Genmab gets CHMP opinion recommending marketing authorization of epcoritamab
The FlyGenmab gets CHMP opinion recommending marketing authorization of epcoritamab
6d ago
GMAB
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
PremiumPress Releases
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
6d ago
GMAB
Completion of Share Buy-back Program
PremiumPress Releases
Completion of Share Buy-back Program
7d ago
GMAB
Genmab price target raised to $47 from $46 at BTIG
PremiumThe Fly
Genmab price target raised to $47 from $46 at BTIG
7d ago
GMAB
FDA grants second approval for EPKINLY in r/r follicular lymphoma
PremiumThe Fly
FDA grants second approval for EPKINLY in r/r follicular lymphoma
8d ago
ABBV
GMAB
FDA grands second approval for AbbVie’s EPKINLY in follicular lymphoma Genmab
PremiumThe FlyFDA grands second approval for AbbVie’s EPKINLY in follicular lymphoma Genmab
8d ago
ABBV
GMAB
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
PremiumPress Releases
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
8d ago
GMAB
Genmab’s Epkinly gets FDA accelerated approval for lymphoma
PremiumThe Fly
Genmab’s Epkinly gets FDA accelerated approval for lymphoma
8d ago
GMAB
Transactions in Connection with Share Buy-back Program
PremiumPress Releases
Transactions in Connection with Share Buy-back Program
10d ago
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
PremiumPress Releases
Capital Increase in Genmab as a Result of Employee Warrant Exercise
16d ago
GMAB
Transactions in Connection with Share Buy-back Program
PremiumPress Releases
Transactions in Connection with Share Buy-back Program
17d ago
GMAB
Genmab management to meet with BTIG
PremiumThe Fly
Genmab management to meet with BTIG
21d ago
GMAB
Grant of Restricted Stock Units and Warrants to Employees in Genmab
PremiumPress ReleasesGrant of Restricted Stock Units and Warrants to Employees in Genmab
22d ago
GMAB
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
PremiumPress Releases
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
23d ago
GMAB
Transactions in Connection with Share Buy-back Program
PremiumPress Releases
Transactions in Connection with Share Buy-back Program
24d ago
GMAB
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
PremiumPress Releases
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
29d ago
GMAB
Genmab price target raised to $53 from $50 at Truist
PremiumThe Fly
Genmab price target raised to $53 from $50 at Truist
1M ago
GMAB
Genmab announces data from innovaTV 207 trial Part C
PremiumThe Fly
Genmab announces data from innovaTV 207 trial Part C
1M ago
GMAB
Transactions in Connection with Share Buy-back Program
PremiumPress Releases
Transactions in Connection with Share Buy-back Program
1M ago
GMAB
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
PremiumPress ReleasesInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
1M ago
GMAB
Genmab announces efficacy, safety data from ongoing Phase 1/2 clinical trials
PremiumThe Fly
Genmab announces efficacy, safety data from ongoing Phase 1/2 clinical trials
1M ago
GMAB
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
PremiumPress Releases
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
1M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >